Last updated on August 2013

Surgery in Treating Patients With Neuroblastoma


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Neuroblastoma
  • Age: - 20 Years
  • Gender: Male or Female
  • Other:
    DISEASE CHARACTERISTICS:
    Trial: Histologically proven International Neuroblastoma Staging System (INSS) stage
    IIA and IIB neuroblastoma without amplification of the N-myc oncogene
    Study: Histologically proven neuroblastoma
    Stage I
    Stage II with amplified N-myc
    Stage II without evaluation of N-myc
    Stage II with symptomatic spinal cord compression
    Stage III
    No metastases diagnosed within 1 month of study
    PATIENT CHARACTERISTICS:
    Age:
    20 and under
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    Not specified
    Chemotherapy:
    No prior chemotherapy
    No adjuvant chemotherapy planned
    Endocrine therapy:
    Prior use of steroids allowed
    Radiotherapy:
    Not specified
    Surgery:
    Not specified
    DISEASE CHARACTERISTICS:
    Trial: Histologically proven International Neuroblastoma Staging System (INSS) stage
    IIA and IIB neuroblastoma without amplification of the N-myc oncogene
    Study: Histologically proven neuroblastoma
    Stage I
    Stage II with amplified N-myc
    Stage II without evaluation of N-myc
    Stage II with symptomatic spinal cord compression
    Stage III
    No metastases diagnosed within 1 month of study
    PATIENT CHARACTERISTICS:
    Age:
    20 and under
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    Not specified
    Chemotherapy:
    No prior chemotherapy
    No adjuvant chemotherapy planned
    Endocrine therapy:
    Prior use of steroids allowed
    Radiotherapy:
    Not specified
    Surgery:
    Not specified
    DISEASE CHARACTERISTICS:
    Trial: Histologically proven International Neuroblastoma Staging System (INSS) stage
    IIA and IIB neuroblastoma without amplification of the N-myc oncogene
    Study: Histologically proven neuroblastoma
    Stage I
    Stage II with amplified N-myc
    Stage II without evaluation of N-myc
    Stage II with symptomatic spinal cord compression
    Stage III
    No metastases diagnosed within 1 month of study
    PATIENT CHARACTERISTICS:
    Age:
    20 and under
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    Not specified
    Chemotherapy:
    No prior chemotherapy
    No adjuvant chemotherapy planned
    Endocrine therapy:
    Prior use of steroids allowed
    Radiotherapy:
    Not specified
    Surgery:
    Not specified
    DISEASE CHARACTERISTICS:
    Trial: Histologically proven International Neuroblastoma Staging System (INSS) stage
    IIA and IIB neuroblastoma without amplification of the N-myc oncogene
    Study: Histologically proven neuroblastoma
    Stage I
    Stage II with amplified N-myc
    Stage II without evaluation of N-myc
    Stage II with symptomatic spinal cord compression
    Stage III
    No metastases diagnosed within 1 month of study
    PATIENT CHARACTERISTICS:
    Age:
    20 and under
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    Not specified
    Chemotherapy:
    No prior chemotherapy
    No adjuvant chemotherapy planned
    Endocrine therapy:
    Prior use of steroids allowed
    Radiotherapy:
    Not specified
    Surgery:
    Not specified
    DISEASE CHARACTERISTICS:
    Trial: Histologically proven International Neuroblastoma Staging System (INSS) stage
    IIA and IIB neuroblastoma without amplification of the N-myc oncogene
    Study: Histologically proven neuroblastoma
    Stage I
    Stage II with amplified N-myc
    Stage II without evaluation of N-myc
    Stage II with symptomatic spinal cord compression
    Stage III
    No metastases diagnosed within 1 month of study
    PATIENT CHARACTERISTICS:
    Age:
    20 and under
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    Not specified
    Chemotherapy:
    No prior chemotherapy
    No adjuvant chemotherapy planned
    Endocrine therapy:
    Prior use of steroids allowed
    Radiotherapy:
    Not specified
    Surgery:
    Not specified
    DISEASE CHARACTERISTICS:
    Trial: Histologically proven International Neuroblastoma Staging System (INSS) stage
    IIA and IIB neuroblastoma without amplification of the N-myc oncogene
    Study: Histologically proven neuroblastoma
    Stage I
    Stage II with amplified N-myc
    Stage II without evaluation of N-myc
    Stage II with symptomatic spinal cord compression
    Stage III
    No metastases diagnosed within 1 month of study
    PATIENT CHARACTERISTICS:
    Age:
    20 and under
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    Not specified
    Chemotherapy:
    No prior chemotherapy
    No adjuvant chemotherapy planned
    Endocrine therapy:
    Prior use of steroids allowed
    Radiotherapy:
    Not specified
    Surgery:
    Not specified
    DISEASE CHARACTERISTICS:
    Trial: Histologically proven International Neuroblastoma Staging System (INSS) stage
    IIA and IIB neuroblastoma without amplification of the N-myc oncogene
    Study: Histologically proven neuroblastoma
    Stage I
    Stage II with amplified N-myc
    Stage II without evaluation of N-myc
    Stage II with symptomatic spinal cord compression
    Stage III
    No metastases diagnosed within 1 month of study
    PATIENT CHARACTERISTICS:
    Age:
    20 and under
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    Not specified
    Chemotherapy:
    No prior chemotherapy
    No adjuvant chemotherapy planned
    Endocrine therapy:
    Prior use of steroids allowed
    Radiotherapy:
    Not specified
    Surgery:
    Not specified
    DISEASE CHARACTERISTICS:
    Trial: Histologically proven International Neuroblastoma Staging System (INSS) stage
    IIA and IIB neuroblastoma without amplification of the N-myc oncogene
    Study: Histologically proven neuroblastoma
    Stage I
    Stage II with amplified N-myc
    Stage II without evaluation of N-myc
    Stage II with symptomatic spinal cord compression
    Stage III
    No metastases diagnosed within 1 month of study
    PATIENT CHARACTERISTICS:
    Age:
    20 and under
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    Not specified
    Chemotherapy:
    No prior chemotherapy
    No adjuvant chemotherapy planned
    Endocrine therapy:
    Prior use of steroids allowed
    Radiotherapy:
    Not specified
    Surgery:
    Not specified

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.